Elite Pharmaceuticals Inc (ELTP)

[rollin2nyte]

It's not rocket science, just add a once-a-day oxycodone bead w/ a naltrexone bead and you have a once-a-day abuse resistant product. Therefore, ELI-200 represents three products. I wonder how difficult this is to replicate with morphine?

Answer: Pretty f'in easy

I'll say this again, we're not colonizing Mars here.

And did we tell you the name of the game, boy?
We call it 'riding the gravy train' - Pink Floyd

http://biotuesdays.com/2013/08/06/elite-eyes-home-run-in-abuse-resistant-technology/

"Elite also has commercially scaled up a once-daily formulation of oxycodone, which currently doesn’t exist on the U.S. market. “I don’t think it takes a whole lot of imagination to realize that once we’ve demonstrated that we can develop an abuse-resistant formulation that’s twice-a-day, it’s not that hard to combine the once-a-day oxycodone bead with a naltrexone bead and hence you also have a once-a-day abuse-resistant formulation. So, oxycodone actually represents three products for us.”

Mr. Treppel recalls that Elite previously tried to license the once-a-day formulation in the European market and had found a partner. “At that time, we didn’t have the financial wherewithal to pursue that opportunity. It’s fair to say that that opportunity may get looked at again because there are opportunities overseas, especially the European and Asian markets for opioids.”
In addition, he says Elite is working on an abuse-resistant morphine molecule. “A non-abuse formulation and an abuse formulation are currently on the market, so that one molecule represents two product opportunities for us,” he adds.

“We’re not reinventing the wheel with every product, which is really the position that our competitors are in,” he contends. “Every time they try and develop one of these abuse-resistant opioid products, each one is unique and requires a unique approach. We don’t see it that way. We think we have a platform. We take a particular opioid molecule and develop an extended release formulation. We already have the naltrexone bead, so we put them in a capsule and we have a potential product.”